NCT03501979 2025-08-29Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMDUniversity of Alabama at BirminghamPhase 2 Terminated17 enrolled 16 charts
NCT05091528 2022-08-18A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersSilverback TherapeuticsPhase 1/2 Terminated2 enrolled 9 charts